← Back to Search

Cholinesterase Inhibitor

Donepezil for Anorexia

Phase 2
Waitlist Available
Research Sponsored by New York State Psychiatric Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 18-60 years (Clinical interview)
Diagnosed with anorexia nervosa (EDA-5)
Must not have
History of peptic ulcer disease (clinical interview)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment to the end of treatment at 8 weeks
Awards & highlights
No Placebo-Only Group

Summary

"This trial will test whether donepezil is safe and well-tolerated for patients with anorexia nervosa. Patients will receive increasing doses of the medication over 8 weeks and will be closely

Who is the study for?
This trial is for individuals with anorexia nervosa receiving care at the New York State Psychiatric Institute Eating Disorders Unit. Participants will be given donepezil, starting at 1 mg per day and potentially increasing to 5 mg daily over 8 weeks.
What is being tested?
The study aims to test the feasibility and tolerability of donepezil in patients with anorexia nervosa. The medication dosage may increase gradually, and changes in maladaptive eating habits will be monitored throughout the treatment.
What are the potential side effects?
Participants will be closely watched for side effects by a psychiatrist weekly. Specific side effects are not listed but typically could include nausea, headaches, or other reactions to the medication.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 60 years old.
Select...
I have been diagnosed with anorexia nervosa.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had peptic ulcers in the past.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment to the end of treatment at 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment to the end of treatment at 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinical Global Impressions Scale
Side Effects Form
Secondary study objectives
Food Choice Task
Self-Report Habit Index

Side effects data

From 2009 Phase 4 trial • 220 Patients • NCT00177671
1%
Suicide Attempt
1%
Myocardial infarcation with congestive heart failure
1%
stroke
100%
80%
60%
40%
20%
0%
Study treatment Arm
Donepezil
Placebo

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open LabelExperimental Treatment1 Intervention
Donepezil
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Donepezil
2011
Completed Phase 4
~2070

Find a Location

Who is running the clinical trial?

New York State Psychiatric InstituteLead Sponsor
478 Previous Clinical Trials
153,963 Total Patients Enrolled
17 Trials studying Eating Disorders
788 Patients Enrolled for Eating Disorders
~7 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top